Synageva completes enrollment in lysosomal acid lipase deficiency trial

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Synageva BioPharma (GEVA) completes enrollment in a Phase 3 study of sebelipase alfa in LAL Deficiency.

Top-line results now expected in H2 2014. (PR)